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Abstract
Background:  Antiretroviral therapy (ART) with a generic fixed-dose combination (FDC) of
stavudine (d4T)/lamivudine (3TC)/nevirapine (NVP) is widely used in developing countries. The
clinical data of this FDC among very advanced HIV-infected patients is limited.
Methods: A retrospective cohort study was conducted among ART-naïve HIV-infected patients
who were initiated a generic FDC of d4T/3TC/NVP between May 2004 and October 2005. Patients
were categorized into 2 groups according to the baseline CD4 (group A: <50 cell/mm3 and group
B: ≥ 50 cell/mm3).
Results: There were 204 patients with a mean ± SD age of 37.1 ± 8.9 years, 120 (58.8%) in group
A and 84 (41.2%) in group B. Median (IQR) CD4 cell count was 6 (16–29) cells/mm3 in group A and
139 (92–198) cells/mm3 in group B. Intention-to-treat analysis at 48 weeks, 71.7% (86/120) of group
A and 75.0% (63/84) of group B achieved plasma HIV RNA <50 copies/ml (P = 0.633). On-
treatment analysis, 90.5% (87/96) in group A and 96.9% (63/65) in group B achieved plasma HIV
RNA <50 copies/ml (P = 0.206). At 12, 24, 36 and 48 weeks of ART, mean CD4 were 98, 142, 176
and 201 cells/mm3 in group A and 247, 301, 336 and 367 cells/mm3 in group B, respectively. There
were no differences of probabilities to achieve HIV RNA <50 copies/ml (P = 0.947) and CD4
increment at 48 weeks between the two groups (P = 0.870). Seven (9.6%) patients in group A and
4 (8.5%) patients in group B developed skin reactions grade II or III (P = 1.000). ALT at 12 weeks
was not different from that at baseline in both groups (P > 0.05).
Conclusion: Initiation of FDC of d4T/3TC/NVP in HIV-infected patients with CD4 <50 and ≥ 50
cells/mm3 has no different outcomes in terms of safety and efficacy. FDC of d4T/3TC/NVP can be
effectively used in advance HIV-infected patients with CD4 <50 cells/mm3.
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Background
Current antiretroviral treatment guidelines for HIV infec-
tion in adults and adolescents in the resource-limited set-
tings recommend using two nucleoside reverse
transcriptase inhibitors (NRTIs) plus one non-nucleoside
reverse transcriptase inhibitor (NNRTI) as the first-line
antiretroviral regimen [1,2]. Regimens based on these
combinations are efficacious, are generally less expensive,
have generic formulations and are available as generic
fixed-dose combinations (FDC). To date, two NNRTIs are
currently available for clinical use in the treatment of HIV
disease. Either nevirapine (NVP) or efavirenz (EFV) has
shown antiretroviral efficacy [3-5]. A recent large investi-
gation has demonstrated that both drugs have similar
antiviral efficacy among antiretroviral naïve HIV-infected
patients [5].
Although EFV-based ART is an NNRTI-based antiretroviral
therapy (ART) of choice according to the recommenda-
tion of recent antiretroviral treatment guidelines [1,2],
NVP-based HAART has been extensively used in the devel-
oping countries due to its accessibility. Since 2002, the
Thai Government Pharmaceutical Organization (GPO)
has produced a FDC of 30 or 40 mg stavudine (d4T), 150
mg lamivudine (3TC) and 200 mg nevirapine (NVP). This
combination formula makes dosing simple (one tablet
twice daily) and facilitates drug supply procedure for the
national ART program. The previous study of bio-equiva-
lence showed that NVP concentrations were within inter-
national and manufacturer's standard [6]. In addition,
World Health Organization (WHO) guideline recom-
mends a combination of two nucleoside reverse tran-
scriptase inhibitors (NRTIs) and one NNRTI as first-line
regimen in resource-poor settings due to available evi-
dences, clinical experience and programmatic feasibility
for the wider introduction of ART [7]. The Medecins Sans
Frontieres (MSF) cohort result recently demonstrated the
efficacy and safety of generic FDC in preventing AIDS-
related death in resource-limited settings [8].
There are some potential limitations of NVP-based ART
including adverse drug reactions and low genetic barrier.
Skin rash is the most frequently observed adverse event
from NVP and manifests as a diffuse maculopapular rash
or erythematous rash with or without constitutional
symptoms. The risk of rash at any severity is greatest in the
first six weeks [9]. However, the severe rashes have been
reported [10-13].
To date, the data regarding safety and efficacy of the d4T/
3TC/NVP FDC among advanced HIV-infected patients
with very low CD4 is still limited. Patients in resource-
limited settings usually present late with very low CD4 cell
counts. We therefore conducted this retrospective cohort
study to compare immunological and virological out-
comes and adverse events of a generic FDC of d4T/3TC/
NVP between HIV-infected patients who had baseline
CD4 cell counts <50 cells/mm3 and those who had CD4
cell counts ≥50 cells/mm3.
Methods
A retrospective cohort study was conducted among ART-
naïve HIV-infected patients who were initiated a generic
FDC of d4T/3TC/NVP between May 2004 and October
2005 in Bamrasnaradura Infectious Diseases Institute,
Ministry of Public Health, Nonthaburi, Thailand. The
patients' identification numbers were identified from
annual database of the institute. The data were extracted
from the medical records. Inclusion criteria were as fol-
lows: (1) HIV-infected individuals ≥ 15 years old, (2)
naïve to ART prior to FDC of d4T/3TC/NVP, (3) were ini-
tiated with a generic FDC of d4T/3TC/NVP, (4) used sep-
arate tablet of NVP 200-mg once-daily lead-in dose during
the first 2 weeks, prior to escalation to 200 mg twice daily,
(5) followed up at least two clinic visit. Exclusion criteria
were as follows: (1) baseline serum creatinine level > 2.0
mg/ml, (2) baseline liver aminotransferase >3 times of
upper normal limit, (3) currently active major opportun-
istic infections (OIs), and (4) receiving medications that
have drug-drug interactions with NVP, including
rifampicin and fluconazole.
All eligible patients were categorized into two groups
according to their baseline CD4 cell counts: group A (CD4
cell count <50 cells/mm3) and group B (CD4 cell counts
≥ 50 cells/mm3). Factors including demographics, previ-
ous OIs, CD4 cell counts, plasma HIV RNA were studied
and compared between the two groups. Patients were fol-
lowed up for 48 weeks after initiation of a generic FDC of
d4T/3TC/NVP. The parameters including CD4 cell counts,
plasma HIV RNA and ALT were assessed at baseline, 12,
24, 36 and 48 weeks of ART. The primary outcome of
interest was the proportion of patients who achieved
plasma HIV RNA <50 copies/ml after 48 weeks of ART.
The secondary outcomes were as follows: 1) the probabil-
ity to achieve plasma HIV RNA <50 copies/ml, 2) the
increment of the number of CD4 cell counts at 48 weeks
of ART from baseline value and 3) the incidences of NVP-
associated adverse reactions including skin rashes and
hepatotoxicity that lead to drug discontinuation.
The severity of skin rashes was determined as Level I: ery-
thema; Level II: diffuse maculopapular rash or urticaria;
Level III: rash with constitutional symptoms,
angioedema, serum sickness-like reactions, Stevens John-
son syndrome; Level IV: toxic epidermal necrolysis. The
virological failure was defined as either a rebound plasma
HIV RNA of >1,000 copies/ml after having previously
undetectable value or lack of achievement to <50 copies/
ml at 24 weeks of ART.AIDS Research and Therapy 2007, 4:6 http://www.aidsrestherapy.com/content/4/1/6
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Mean (± SD), median (interquartile range, IQR) and fre-
quencies (%) were used to describe patients' characteris-
tics in both groups. Chi-square test and Mann-Whitney U
test were used to compare categorical variables and con-
tinuous variables between the two groups, respectively.
The proportion of patients with plasma HIV RNA <50
copies/ml after 48 weeks of ART were analyzed as inten-
tion-to-treat and on-treatment analysis. Missing data on
plasma HIV RNA levels were taken to be greater than 50
copies/mL. The increment of CD4 cell counts between the
two groups were compared by Mann-Whitney U test. The
Kaplan-Meier test was used to estimate the probability of
undetectable plasma HIV RNA at 12, 24, 36 and 48 weeks
after ART and the median time to undetectable plasma
HIV RNA. The patients were censored when they had viro-
logical failure or discontinued the FDC due to any causes.
The patients who had been on drug holidays longer than
4 weeks were considered as lost to follow-up and censored
at the date of first lost to follow-up visit. The log-rank test
was used to compare the median time to undetectable
plasma HIV RNA between the two groups. The multivari-
ate Cox proportional hazard model was used to determine
the chance of undetectable plasma HIV RNA after receiv-
ing treatment by adjusting for confounding factors, i.e.
age, gender, previous OIs, baseline hemoglobin, CD4 cell
counts (<50 versus ≥ 50 cells/mm3) and plasma HIV RNA
at baseline. Statistical calculations were performed using
SPSS program version 11.5 (SPSS Inc., Chicago, Illinois,
U.S.A). A two-sided P value of less than 0.05 was consid-
ered statistically significant. The study was approved from
the institute review board.
Results
A total of 204 patients met entry criteria; mean (± SD) age
was 37.1 ± 8.9 years and 60.3% were male. There were 120
(58.8%) patients in group A and 84 (41.2%) patients in
group B. Table 1 shows baseline characteristics between
the two groups. Median (IQR CD4 cell count was 6 (16–
29) cells/mm3 in group A and 139 (92–198) cells/mm3 in
group B. Group A had more previous opportunistic infec-
tions, higher baseline HIV RNA, ALP and ALT than group
B (P < 0.05). Any causes of discontinuation of ART are
shown in Table 2. There were no differences of the causes
of discontinuation between the two groups. Of 204
patients, 162 patients had ALT values at 12 weeks after
ART. Two of 95 (2.1%) patients in group A and 1 of 64
(1.6%) patients in group B had ALT elevation at grade 3–
4 (P = 1.000).
The results of the primary outcome are shown in Table 3.
There were no differences of proportion of patients who
achieved plasma HIV RNA <50 copies/ml between the
two groups, either in intention-to-treat analysis or on-
treatment analysis. Cox regression of possible risk factors
for achieving undetectable plasma HIV RNA is shown in
Table 4. The results of Kaplan-Meier analysis to estimate
the probability of undetectable plasma HIV RNA after
receiving treatment are shown in Figure 1. We found that
such probabilities at 12-, 24- and 36-month were 65.1%,
92.4% and 92.4% for group A. The corresponding values
were 67.6%, 89.7% and 89.7% for group B. There was no
difference between the two groups (log rank test, P  =
0.947). The Cox proportional hazard model including
factors of age, gender, body weight, previous OIs, baseline
hemoglobin, baseline CD4 cell counts and baseline
plasma HIV RNA showed that patients in group A had
similar chance of undetectable plasma HIV RNA with the
patients in group B (HR = 0.986, 95%CI = 0.669–1.391, P
= 0.934). The other factors were not associated with unde-
tectable plasma HIV RNA after 48 weeks of ART (P > 0.05).
Group A patients had a median CD4 cell count of 85, 125,
158 and 198 cells/mm3 and group B patients had a
median CD4 of 240, 280, 305 and 331 cells/mm3 at 12,
24, 36 and 48 weeks, respectively (Figure 2). The incre-
ment of median (IQR) CD4 cell counts at 48 weeks from
baseline values were not different between the two groups
[179 (121–226) cells/mm3 vs. 168 (99–273) cells/mm3,
P = 0.870]. Eleven (9.2%) patients in group A and 12
(14.3%) patients in group B developed NVP-associated
skin reactions grade II and III in which lead to the discon-
tinuation of generic FDC of d4T/3TC/NVP (P = 1.000).
Mean ± SD ALT when these 23 patients developed skin
reaction was 31.5 ± 21.1 U/l. No patients in the present
study developed skin reactions grade IV. By repeated
measurement analysis, there were no differences of ALT at
12 weeks from baseline value in both groups (P > 0.05).
No patients developed clinical hepatitis. Three (2.5%)
patients in group A and 5 (6.0%) patients in group B
developed stavudine-associated peripheral neuropathy (P
= 0.278). Stavudine-associated symptomatic lactic acido-
sis was observed in 2 patients during the 48-week study
period. Four patients in group A and one patient in group
B died during the study period. The causes of death of
these 5 patients were as follows: disseminated histoplas-
mosis 1, E. coli sepsis 1, MAC infection 1 and wasting syn-
dromes 2.
Discussion
The results from the present study demonstrate that HIV-
infected patients who had baseline CD4 cell counts <50
cells/mm3  had similar virological and immunological
responses when compared to those who had baseline
CD4 cell counts ≥ 50 cells/mm3. This finding can support
the use of this generic FDC of d4T/3TC/NVP in very
advanced HIV-infected patients in the resource-limited
settings. According to the guideline for management of
HIV-infected patients in Thailand, ART is recommended
for all patients with history of AIDS-defining illness or
asymptomatic patients with CD4 cells count less than 200AIDS Research and Therapy 2007, 4:6 http://www.aidsrestherapy.com/content/4/1/6
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cell/mm3. Therefore, almost all patients in group B have
baseline CD4 cell counts between 50 cells/mm3 and 200
cells/mm3. As expected, group A patients have a higher
proportion of previous opportunistic infections and a
higher level of plasma HIV RNA.
The overall proportion of patients who achieved plasma
HIV RNA <50 copies/ml was 73% (149 of 204) after 48
weeks of ART in an ITT analysis. Despite the fact that
group A patients were severely immunocompromised
(median baseline CD4 cell count of 6 cells/mm3), we
found that 71% of patients achieved undetectable plasma
HIV RNA after 48 weeks of ART. This number is compara-
ble to the virological response in group B and similar to
other studies that conducted in our country and in devel-
oped countries [5,14-16]. Moreover, this outcome is con-
firmed by the analysis of probability of achieving plasma
HIV RNA <50 copies/ml as shown in Figure 1. Although
the patient in group A had a significantly higher baseline
plasma HIV RNA than that in group B, the rates of achiev-
ing undetectable plasma HIV RNA are not different
between group A and group B, by either univariate or mul-
tivariate analysis.
The well-established predictors of long-term virological
success include potency of ART regimen, adherence to
treatment, low baseline viremia, higher baseline CD4 cell
counts and rapid reduction of viremia in response to treat-
ment [17,18]. In the present study, the difference baseline
CD4 cell counts and baseline plasma HIV-RNA did not
affect virological responses after 48 weeks of treatment.
This may be explained by the fact that this study did not
include patients with CD4 cell count of greater than 200
cells/mm3, as in previous studies. HIV-infected patients in
developing countries usually present late with low CD4
cell counts as previously mentioned. A recent study in a
developing country also demonstrated that there was a
high rate of virological and immunological success after
six months of HAART, irrespective of the pre-HAART viral
load and CD4 cell count [19].
Overall, CD4 cell counts rise with immune recovery from
receiving ART. The increment of CD4 cell counts after 48
weeks of ART is not blunted with very low baseline CD4
cell counts as shown in Figure 2. Even in subgroup of
patient with baseline CD4 cell counts less than 10 cells/
mm3, they can achieve effective immune recovery by given
sufficient time after initiation of ART. Median (IQR) CD4
cell counts increase from 5 (3–7) cells/mm3 to 151 (92–
231) cells/mm3 in this subgroup (data not shown). This
response would be continued for many years into effective
antiviral effect of ART.
Regarding discontinuation of ART, NVP-associated skin
rashes is an important reason for discontinuation. In the
present of NVP 200-mg once-daily lead-in for 2 weeks,
Table 1: Baseline characteristics of 204 patients
Characteristics Group A (n = 120) Group B (n = 84) P value
Age, years, mean ± SD 37.6 ± 8.0 36.9 ± 10.1 0.289
Male gender 70 (58.3%) 53 (63.1%) 0.561
Body weight, Kgs, mean ± SD 54.3 ± 10.3 56.1 ± 13.8 0.766
Previous major OIs 41 (34.2%) 11 (13.1%) 0.001
Baseline hemoglobin, mg/dl, median (IQR) 10.7 (8.4–12.0) 11.5 (9.5–13.3) 0.035
Baseline CD4, cell/mm3, median(IQR) 6 (16–29) 139 (92–198) <0.001
Baseline CD4%, median (IQR) 2 (1–2) 8 (0–13) <0.001
Baseline plasma HIV RNA, copies/ml, median (IQR) 357,000 (187,000–727,750) 231,000 (69,750–645,250) 0.027
Baseline ALP, U/I, median (IQR) 91.0 (71.0–128.0) 74.5 (58.0–94.2) <0.001
Baseline ALT, U/I, median (IQR) 32.0 (18.0–50.0) 21.5 (16.0–33.5) 0.003
Baseline total bilirubin, mg/dL, median (IQR) 0.5 (0.4–0.7) 0.5 (0.4–0.7) 0.532
Table 2: Causes of ART discontinuation between the 2 groups
Causes of discontinuation Group A (n = 120) Group B (n = 84) P value
NVP-associated skin rashes grade II, III and IV 11 (9.2%) 12 (14.3%) 0.269
Virological failure 9 (7.5%) 2 (2.4%) 0.129
Lost to follow-up 7 (5.8%) 5 (6.0%) 1.000
Died 4 (3.3%) 1 (1.2%) 0.651
Referred to other hospitals 1 (0.8%) 0* 1.000
d4T-associated lactic acidosis 1 (0.8%) 1 (1.2%) 1.000
* Substitute 0 as 1 to calculate P valueAIDS Research and Therapy 2007, 4:6 http://www.aidsrestherapy.com/content/4/1/6
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NVP may cause a mild skin rash in 15 to 20% of patients;
5 to 10% of which discontinue treatment [5,20,21]. After
48 weeks of ART, 11.3% of patients in the present study
developed skin rashes in which lead to permanent discon-
tinuation of NVP. This rate is similar to that in the previ-
ous study in Thais [14,22]. Of note, Steven-Johnson's
syndrome and toxic epidermal necrolysis were not
observed in this cohort in whom almost all of patients
(91%) in the study had baseline CD4 cell counts less than
200 cells/mm3. Furthermore, no factors (i.e., gender and
CD4 cell counts) were associated with skin rashes in the
present study according to the results of logistic regression
Probability of undetectable plasma HIV RNA between the 2 groups Figure 1
Probability of undetectable plasma HIV RNA between the 2 groups.
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Table 3: Virological response between the two treatment groups at 48 weeks
Percentage of patients who achieved HIV RNA< 50 copies/ml Relative Risk, 95% confidence interval P value
Group A Group B
ITT* 71.7% (86/120) 75.0% (63/84) 0.843, 0.447–1.589 0.633
OT** 90.6% (87/96) 96.9% (63/65) 0.303, 0.063–1.453 0.202
* Intention-to-treat analysis ** On-treatment analysisAIDS Research and Therapy 2007, 4:6 http://www.aidsrestherapy.com/content/4/1/6
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analysis (data not shown). These findings suggest that
there is no clinical factor to predict the occurrence of rash
from NVP in patients with very low CD4 cell counts. How-
ever, this should be interpreted with caution due to the
limitation of sample size. It would be beneficial if there
are any factors that can predict this adverse event. Further
study to determine immunologic and genetic factors that
associated with rash is encouraged.
Although there are limited data regarding the impact on
hepatotoxicity, we decided to exclude the patients who
concurrently received rifampicin and fluconazole from
the study. These drugs may potentially increase incidence
of hepatotoxicity [23-25]. The previous studies demon-
strated that woman with higher CD4 cell counts appear to
be at a highest risk. A 12-fold higher incidence of sympto-
matic events was seen in woman with CD4 cell counts of
>250 cells/mm3 at the time of nevirapine initiation when
compared with woman with CD4 cell counts of ≤ 250
cells/mm3 (11.0% vs 0.9%). An increased risk was also
seen in men with baseline CD4 cell counts >400 cells/
mm3 when compare with baseline CD4 cell counts ≤ 400
cells/mm3 (6.3% vs 1.2%) [26-29]. The present study
show that no patients developed clinical hepatitis after 48
weeks of follow-up. In addition, neither group A patients
nor group B patients had significant increment of liver
enzymes after 12 weeks of ART when compare to baseline
values. Overall, the frequencies of clinical hepatitis and
hepatic laboratory abnormalities were low in both
groups. In the present cohort, stavudine-associated symp-
tomatic lactic acidosis was observed in 2 patients after 48
weeks of treatment. Although this number is low, this
Table 4: Cox regression of possible risk factors for achieving undetectable plasma HIV RNA at 48 weeks
Risk factors HR 95% CI P value
Age 1.000 0.980–1.020 0.993
Gender 0.948 0.661–1.513 0.774
Weight 0.998 0.983–1.013 0.778
Previous OIs 0.979 0.660–1.451 0.916
Hemoglobin 1.000 1.000–1.000 0.533
Baseline CD4 cell counts<50 cells/
mm3
1.000 0.998–1.002 0.880
Baseline log plasma HIV-RNA 0.764 0.549–1.064 0.111
HR = Hazard ratio, 95% CI = 95% Confidence interval
Immunological outcomes between the 2 groups at 48 weeks of ART Figure 2
Immunological outcomes between the 2 groups at 48 weeks of ART.
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well-established adverse event should be closely moni-
tored in the further long-termed treatment. Currently, sta-
vudine is not a first-line antiretroviral drug recommended
in the recent guideline of developed country due to its sig-
nificant toxicities [7]. Additionally, eight patients needed
to discontinue stavudine due to peripheral neuropathy.
Until more options are accessible, stavudine is still a part
of a simplified strategy for scaling-up ART in resource-
poor settings according to previously mentioned benefits.
The study has demonstrated the satisfactory clinical out-
comes, the extent of immunological restoration and viro-
logical responses of a generic FDC of d4T/3TC/NVP in
very advanced HIV-infected patients. These results provide
the evidence of benefit from NVP-based ART in advanced
HIV-infected patients. Thus, this may support the physi-
cians to prescribe NVP-based ART regimen for these
patients.
The present study has some limitations. The study design
is a retrospective study, which is not the best study design
to evaluate the efficacy of antiretroviral regimen. How-
ever, this study design is a comparative study that evalu-
ated the efficacy NVP-based ART between the patients
who had extremely low CD4 cell counts and those who
had moderate level of CD4 cell counts. The results of the
present study may provide useful clinical data for caring
advanced HIV-infected patients in developing countries.
In addition, some clinical data may be underestimated
and some possible risk factors may not be included. Our
study was based on a tertiary care center for HIV-infected
patients. These study populations were cared by infectious
diseases specialists and HIV-experienced medical team.
Thus, the similar results might not be achieved in the gen-
eral or community hospital in resource-limited setting.
Liver enzymes were not performed during the first few
weeks of ART. However, no patients developed clinical
hepatitis during this period. Baseline hepatitis B and hep-
atitis C serology were not routinely performed prior to
ART initiation. We did not have reference group of
patients with CD4 cell counts greater than 200 cells/mm3.
It would be more interesting if we can compare clinical
outcomes between these groups. Finally, the sample size
may be not large enough to detect small difference of effi-
cacy and low incidence of adverse events, particularly hep-
atitis.
In conclusion, initiation of a FDC of d4T/3TC/NVP in
HIV-infected patients with baseline CD4 cell count of <50
and ≥ 50 cells/mm3 has no different outcomes in terms of
safety and 48-week virological and immunological
response. Generic FDC of d4T/3TC/NVP can be effectively
used in advance HIV-infected patients with CD4 <50 cells/
mm3.
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